A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin.
Cell separation
Lectin
Pluripotent stem cell
rBC2LCN
Journal
Regenerative therapy
ISSN: 2352-3204
Titre abrégé: Regen Ther
Pays: Netherlands
ID NLM: 101709085
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
05
12
2019
revised:
27
02
2020
accepted:
11
03
2020
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
29
5
2020
Statut:
epublish
Résumé
Tumourigenesis attributed to residual undifferentiated cells in a graft is considered to be a significant issue in cell therapy using human pluripotent stem cells. To ensure the safety of regenerative medicine derived from pluripotent stem cells, residual undifferentiated cells must be eliminated in the manufacturing process. We previously described the lectin probe rBC2LCN, which binds harmlessly and specifically to the cell surface of human pluripotent stem cells. We report here a technique using rBC2LCN to remove pluripotent cells from a heterogenous population to reduce the chance of teratoma formation. We demonstrate a method for separating residual tumourigenic cells using rBC2LCN-bound magnetic beads. This technology is a novel use of their previous discovery that rBC2LCN is a lectin that selectively binds to pluripotent cells. We optimize and validate a method to remove hPSCs from a mixture with human fibroblasts using rBC2LCN-conjugated magnetic beads. Cells with the potential to form teratoma could be effectively eliminated from a heterogeneous cell population with biotin-labelled rBC2LCN and streptavidin-bound magnetic beads. The efficiency was measured by FACS, ddPCR, and animal transplantation, suggesting that magnetic cell separation using rBC2LCN is quite efficient for eliminating hPSCs from mixed cell populations. The removal of residual tumourigenic cells based on rBC2LCN could be a practical option for laboratory use and industrialisation of regenerative medicine using human pluripotent stem cells.
Identifiants
pubmed: 32462059
doi: 10.1016/j.reth.2020.03.017
pii: S2352-3204(20)30041-9
pmc: PMC7240284
doi:
Types de publication
Journal Article
Langues
eng
Pagination
306-314Subventions
Organisme : NCHHSTP CDC HHS
ID : UA1 PS000063
Pays : United States
Informations de copyright
© 2020 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Nat Med. 2006 Nov;12(11):1259-68
pubmed: 17057709
Stem Cell Res. 2009 May;2(3):198-210
pubmed: 19393593
Stem Cells. 2005 Oct;23(9):1242-50
pubmed: 16210408
Cell Stem Cell. 2013 Feb 7;12(2):167-79
pubmed: 23318055
Nature. 2017 Aug 30;548(7669):592-596
pubmed: 28858313
Stem Cells Dev. 2009 Jan-Feb;18(1):47-54
pubmed: 18393673
Stem Cells. 2008 Jun;26(6):1454-63
pubmed: 18356574
Circulation. 2013 Sep 10;128(11 Suppl 1):S87-94
pubmed: 24030425
N Engl J Med. 2017 Mar 16;376(11):1038-1046
pubmed: 28296613
Structure. 2010 Jan 13;18(1):59-72
pubmed: 20152153
Regen Ther. 2015 Oct 27;2:17-23
pubmed: 31245455
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Hybridoma. 1984 Winter;3(4):347-61
pubmed: 6396197
Cell Res. 2011 Nov;21(11):1551-63
pubmed: 21894191
Nat Biotechnol. 2011 Aug 14;29(9):829-34
pubmed: 21841799
Stem Cell Reports. 2015 May 12;4(5):811-20
pubmed: 25866158
J Biol Chem. 2011 Jun 10;286(23):20345-53
pubmed: 21471226
Sci Rep. 2016 Sep 09;6:32532
pubmed: 27608814
Science. 1998 Nov 6;282(5391):1145-7
pubmed: 9804556
Nat Rev Cancer. 2011 Apr;11(4):268-77
pubmed: 21390058
Science. 2003 May 9;300(5621):913-6
pubmed: 12738841
Circ Res. 2013 Feb 1;112(3):523-33
pubmed: 23371901
PLoS One. 2014 Mar 19;9(3):e85039
pubmed: 24647085
J Cereb Blood Flow Metab. 2010 Aug;30(8):1487-93
pubmed: 20216552
Stem Cell Rev Rep. 2009 Mar;5(1):72-80
pubmed: 19184635
Cell Transplant. 2011;20(6):883-91
pubmed: 21054935
Stem Cells. 2009 Aug;27(8):1792-801
pubmed: 19544435
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):E3281-90
pubmed: 23918355
Stem Cells. 2003;21(3):257-65
pubmed: 12743320
Biochem Biophys Res Commun. 2013 Feb 15;431(3):524-9
pubmed: 23321312
Curr Protoc Stem Cell Biol. 2007 Oct;Chapter 1:Unit1B.4
pubmed: 18785162
Stem Cell Reports. 2014 Jan 23;2(2):205-18
pubmed: 24527394
Cell Cycle. 2009 Aug 15;8(16):2608-12
pubmed: 19597339
Methods Mol Biol. 2011;767:231-41
pubmed: 21822879
Stem Cells Transl Med. 2013 Apr;2(4):265-73
pubmed: 23526252
Cell Stem Cell. 2014 Apr 3;14(4):535-48
pubmed: 24529595
Sci Rep. 2012;2:964
pubmed: 23236586
Nat Commun. 2013;4:1992
pubmed: 23778593
Biotechnol J. 2010 Jan;5(1):50-61
pubmed: 19946874
Cell Stem Cell. 2011 Jun 3;8(6):618-28
pubmed: 21624806
Nat Med. 2013 Aug;19(8):998-1004
pubmed: 23921754
PLoS One. 2012;7(9):e45532
pubmed: 23049812
Lancet. 2015 Feb 7;385(9967):509-16
pubmed: 25458728
Int J Stem Cells. 2016 Nov 30;9(2):264-270
pubmed: 27871153
Cell Chem Biol. 2017 Jun 22;24(6):685-694.e4
pubmed: 28529132
Molecules. 2017 Jul 10;22(7):
pubmed: 28698527